News
BioNTech announces CureVac acquisition for $1.25 billion in stock to strengthen cancer therapy pipeline and mRNA technology ...
BioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy ...
The BioNTech SE acquisition of CureVac N.V. brings together complementary technologies, as both are developing mRNA ...
German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it ...
Pharmaceutical Technology on MSN1d
BioNTech bolsters mRNA pipeline with $1.25bn CureVac acquisitionBioNTech has agreed to acquire mRNA specialist CureVac for approximately $1.25bn, as the big pharma company amps up its strategy to offer cancer treatments using the modality. According to the deal, ...
Amicus Therapeutics is growing steadily with Galafold and a promising Pompe therapy, targeting $1B revenue by 2028. See why ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback